Abstract:Abstract Since the appearance of the first case of coronavirus disease 2019 (COVID-19) a pandemic has emerged affecting millions of individuals worldwide. Although the main clinical manifestations are respiratory, an increase in neurological conditions, specifically acute cerebrovascular disease, has been detected. We present cerebrovascular disease case incidence in hospitalized patients with SARS-CoV-2 infection. Patients were confirmed by microbiological/serological testing, or on chest CT semiology. Available data on co-morbidity, laboratory parameters, treatment administered, neuroimaging, neuropathological studies and clinical evolution during hospitalization, measured by the modified Rankin scale, were analysed. A bivariate study was also designed to identify differences between ischaemic and haemorrhagic subtypes. A statistical model of binary logistic regression and sensitivity analysis was designed to study the influence of independent variables over prognosis. In our centre, there were 1683 admissions of patients with COVID-19 over 50 days, of which 23 (1.4%) developed cerebrovascular disease. Within this group of patients, cerebral and chest CT scans were performed in all cases, and MRI in six (26.1%). Histological samples were obtained in 6/23 cases (two brain biopsies, and four arterial thrombi). Seventeen patients were classified as cerebral ischaemia (73.9%, with two arterial dissections), five as intracerebral haemorrhage (21.7%), and one leukoencephalopathy of posterior reversible encephalopathy type. Haemorrhagic patients had higher ferritin levels at the time of stroke (1554.3 versus 519.2, P = 0.004). Ischaemic strokes were unexpectedly frequent in the vertebrobasilar territory (6/17, 35.3%). In the haemorrhagic group, a characteristic radiological pattern was identified showing subarachnoid haemorrhage, parieto-occipital leukoencephalopathy, microbleeds and single or multiple focal haematomas. Brain biopsies performed showed signs of thrombotic microangiopathy and endothelial injury, with no evidence of vasculitis or necrotizing encephalitis. The functional prognosis during the hospital period was unfavourable in 73.9% (17/23 modified Rankin scale 4–6), and age was the main predictive variable (odds ratio = 1.5; 95% confidence interval 1.012–2.225; P = 0.043). Our series shows cerebrovascular disease incidence of 1.4% in patients with COVID-19 with high morbidity and mortality. We describe pathological and radiological data consistent with thrombotic microangiopathy caused by endotheliopathy with a haemorrhagic predisposition.

Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients

Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations

An FDA-approved assay platform can detect biomarkers of neuronal and glial injury in the blood of COVID-19 patients

The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2

Neurochemical biomarkers to study CNS effects of COVID-19: A narrative review and synthesis

Biomarkers of Neurological Injury for Emerging Viral Threats and Post Viral Disease

An overview of prognostic value of neurologic and cardiac biomarkers in patients with COVID-19 sequelae

Neurological Complications Associated with the Blood-Brain Barrier Damage Induced by the Inflammatory Response During SARS-CoV-2 Infection

Blood–brain barrier injury and neuroinflammation induced by SARS-CoV-2 in a lung–brain microphysiological system

SARS-CoV-2 and the central nervous system: Emerging insights into hemorrhage-associated neurological consequences and therapeutic considerations

Retrospective Analysis of Blood Biomarkers of Neurological Injury in Human Cases of Viral Infection and Bacterial Sepsis

Author Correction: Blood–brain Barrier Injury and Neuroinflammation Induced by SARS-CoV-2 in a Lung–brain Microphysiological System

Cerebral microbleeds in patients with COVID-19: is there an inevitable connection?

Neuroinflammation in Severe COVID-19: The Dynamics of Inflammatory and Brain Injury Markers During Hospitalization

Biofluid biomarkers of traumatic brain injury

Brain Pathology in COVID-19: Clinical Manifestations and Potential Mechanisms

Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description

Dysregulation of brain and choroid plexus cell types in severe COVID-19

COVID-19 is Associated with an Unusual Pattern of Brain Microbleeds in Critically Ill Patients

Cytokine Storm and Neuropathological Alterations in Patients with Neurological Manifestations of COVID-19

Abstract TMP20: Cerebrovascular Injury Associated With COVID-19 And Non-COVID-19 Acute Respiratory Distress Syndrome